CRT 2019: Rivaroxaban 2.5 MG Bid Combined With DAPT for the Prevention of Death/MI/Stroke

Published: 22 Mar 2019

  • Views:

    Views Icon 1746
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

Dr C. Michael Gibson (Beth Israel Deaconess Medical Center, Boston, MA, US) discusses Rivaroxaban 2.5 mg BID combined with DAPT for the prevention of death/MI/stroke - a patient level data meta-analysis of the ATLAS-ACS-2 TIMI-51 and the COMMANDER HF trials

Filmed on site at CRT 2019 by Radcliffe Cardiology


1. Why did you conduct this analysis?

2. How was data collected and analysed?

3. What were your findings?

4. How does this compliment existing data and what are the implications for practice?